Genelux Corp (GNLX) Stock Price, Quote & News

Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and periton...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 267 9889

Website: www.genelux.com

Address:

2625 Townsgate Road, Suite 230, Westlake Village, United States

CSkaugrud Dec. 3 at 5:28 PM

$GNLX The fireside chat reaffirms my excitement for GNLX. Great things coming!

2 · Reply

thesaltier1 Dec. 2 at 2:45 PM

$GNLX I am about ready to throw in the towel on this one, keep hoping for more positive news to get a bump in price, they said lung cancer news q4, only a few weeks left in the year....my gut feeling says we are going to test the 3's again

1 · Reply

Kupper Nov. 21 at 10:36 PM

$GNLX WTF is going on here. Up during regular day and down AH.

1 · Reply

Kupper Nov. 20 at 5:55 PM

$GNLX so I guess that the jobs report and economy has an impact on stocks that have absolutely nothing to do with that. The world has reached a new level of stupid.

0 · Reply

somaopp Nov. 19 at 8:23 PM

$GNLX is this update already factored in?? -- Lung cancer programs progressing with interim data updates expected in Q4 2025 --

2 · Reply

Kupper Nov. 17 at 5:04 PM

$GNLX this is just stupid. Up 10% down 10%.

0 · Reply

Kupper Nov. 14 at 7:33 PM

$GNLX Daily slow bleed. Some positive news would help.

0 · Reply

Kupper Nov. 13 at 5:03 PM

$GNLX Here comes stop loss raid.

0 · Reply

Kupper Nov. 12 at 6:18 PM

$GNLX this will get played by day traders and penny flippers until lung cancer results are published.

1 · Reply

NoTruceWithTheFuries Nov. 10 at 3:19 PM

$GNLX Everyone who bought above 6/7 is suddenly bearish, big surprise.

0 · Reply

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Aug 7, 2025, 4:20 PM EDT - 4 months ago

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

Jul 7, 2025, 7:00 AM EDT - 5 months ago

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

May 6, 2025, 4:10 PM EDT - 7 months ago

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

Mar 28, 2025, 4:10 PM EDT - 9 months ago

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 25, 2025, 8:31 AM EDT - 9 months ago

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Feb 3, 2025, 6:45 AM EST - 10 months ago

Genelux Corporation Announces New Chief Financial Officer

Dec 13, 2024, 7:01 AM EST - 1 year ago

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Nov 6, 2024, 4:01 PM EST - 1 year ago

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 31, 2024, 10:59 AM EDT - 1 year ago

Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point

Oct 22, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Oct 9, 2024, 4:15 PM EDT - 1 year ago

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

May 24, 2024, 8:00 AM EDT - 1 year ago

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

May 23, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

May 9, 2024, 4:25 PM EDT - 1 year ago

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

$Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer$

Nov 27, 2023, 7:00 AM EST - 2 years ago

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Nov 14, 2023, 5:50 PM EST - 2 years ago

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Sep 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 30, 2023, 1:56 PM EDT - 2 years ago

Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Aug 2, 2023, 4:00 PM EDT - 2 years ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Jul 28, 2023, 10:54 AM EDT - 2 years ago

Why Shares of Genelux Climbed This Week

Jul 20, 2023, 4:45 PM EDT - 2 years ago

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Jul 11, 2023, 4:12 AM EDT - 2 years ago

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

Jul 10, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Jun 29, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Jun 22, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Jun 12, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces $18 Million Private Placement

Jun 1, 2023, 5:19 PM EDT - 2 years ago

Why Shares of Genelux Corporation Jumped This Week

$Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On$

May 25, 2023, 4:01 PM EDT - 2 years ago

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

May 15, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces $33 Million Private Placement

Mar 26, 2023, 10:50 PM EDT - 2 years ago

Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy

Mar 23, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Jan 26, 2023, 6:40 AM EST - 3 years ago

Genelux IPO prices at bottom of range

Jan 25, 2023, 9:00 PM EST - 3 years ago

Genelux Corporation Announces Pricing of Initial Public Offering

Sep 19, 2022, 1:49 PM EDT - 3 years ago

IPO Update: Genelux Finalizes $16 Million IPO Plan

Sep 19, 2022, 9:08 AM EDT - 3 years ago

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

CSkaugrud Dec. 3 at 5:28 PM

$GNLX The fireside chat reaffirms my excitement for GNLX. Great things coming!

2 · Reply

thesaltier1 Dec. 2 at 2:45 PM

1 · Reply

Kupper Nov. 21 at 10:36 PM

$GNLX WTF is going on here. Up during regular day and down AH.

1 · Reply

Kupper Nov. 20 at 5:55 PM

$GNLX so I guess that the jobs report and economy has an impact on stocks that have absolutely nothing to do with that. The world has reached a new level of stupid.

0 · Reply

somaopp Nov. 19 at 8:23 PM

$GNLX is this update already factored in?? -- Lung cancer programs progressing with interim data updates expected in Q4 2025 --

2 · Reply

Kupper Nov. 17 at 5:04 PM

$GNLX this is just stupid. Up 10% down 10%.

0 · Reply

Kupper Nov. 14 at 7:33 PM

$GNLX Daily slow bleed. Some positive news would help.

0 · Reply

Kupper Nov. 13 at 5:03 PM

$GNLX Here comes stop loss raid.

0 · Reply

Kupper Nov. 12 at 6:18 PM

$GNLX this will get played by day traders and penny flippers until lung cancer results are published.

1 · Reply

NoTruceWithTheFuries Nov. 10 at 3:19 PM

$GNLX Everyone who bought above 6/7 is suddenly bearish, big surprise.

0 · Reply

Shakescene1 Nov. 10 at 2:50 PM

$GNLX $GNLX good thing you got out! Got lucky and took my minor loss at 5.73. The doubts about going concern and how far the trial is to being finished. They straight up let their money fall below 1 year cash. That&#39;s huge no-no and signals potential death throes. At best, dilution to soon follow. ~50M

1 · Reply

Kupper Nov. 7 at 6:05 PM

$GNLX Fear creates panic and panic creates overreaction.

0 · Reply

Vavavoom Nov. 7 at 3:47 PM

$GNLX ugh

0 · Reply

Social_Idiot Nov. 7 at 3:40 PM

$GNLX Got lucky and took my minor loss at 5.73. The doubts about going concern and how far the trial is to being finished. They straight up let their money fall below 1 year cash. That's huge no-no and signals potential death throes. At best, dilution to soon follow. ~50M

1 · Reply

JD101 Nov. 7 at 2:52 PM

$GNLX the idiotic shakeout on the eve of data is now done

0 · Reply

Vavavoom Nov. 7 at 3:36 AM

$GNLX hoping for a quick rebound

0 · Reply

Kupper Nov. 7 at 12:58 AM

$GNLX The fundamentals did not change, the financials did not change, the opportunity for success did not change. The only thing that changed was the Top Line release date again. This is and has always been a long term investment.

3 · Reply

Social_Idiot Nov. 6 at 10:10 PM

$GNLX I've not research this company deeply but... What are the thoughts on the BO potential here? I ask because of what today looks like, in context.

1 · Reply

JD101 Nov. 6 at 7:22 PM

$GNLX see this movie before .. shakeout before the data drop

0 · Reply

justiceforb_85 Nov. 6 at 6:49 PM

$GNLX trying to understand the significant reduction in price. Is it mainly driven by the PRROC read-out to second half of 2026 or current cash position... (or both)?

2 · Reply

wallStreetFr Nov. 6 at 4:39 PM

$GNLX Retest 🏀📈

0 · Reply

CSkaugrud Nov. 6 at 4:32 PM

$GNLX Another great buying opportunity.

3 · Reply

Market Cap	179.99M
Revenue (ttm)	10,000.00
Net Income (ttm)	-29.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-298,700.02%
Debt to Equity Ratio	0.00

Volume	135,500
Avg Vol	249,290
Day's Range	N/A - N/A
Shares Out	38.05M
Stochastic %K	16%
Beta	0.06
Analysts	Strong Sell
Price Target	$19.00